Subgroup analysis revealed that CDH11 overexpression is dramatically related to the poor prognosis of GC patients who are at T3 and T4 stages or grade 3 or have a high tumor mutation burden (TMB) (Figure 3). The gene discussed is CDH11; the disease is neoplasm.